Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2006

View Archived Issues

Genta and Emisphere sign licensing agreement for oral gallium compound

Enrollment completed in phase II solid tumor study of CA4P with chemotherapy

Grip strength measurements improve in BioAstin tendonitis study

Noxxon and Pfizer form Spiegelmer product alliance

Pharming to acquire DNage

Reata advances RTA-402 into clinical testing

Paion begins program for next-generation plasminogen activators

Mimetogen completes Series A financing, new licensing agreement

Bioaccelerate Holdings to change name, spin off subsidiaries

Positive opinion handed down in Europe for Ganfort

Exenatide LAR studied for type 2 diabetes in new study

Opposing trends in Oncophage renal cancer phase III trial

CHMP recommends against approval of Zelnorm for IBS-C in Europe

Phase II data for ALGRX-4975 in hernia repair at odds with other phase II results

New dosages of Risperdal M-TAB now available

Rectogesic completes E.U. mutual recognition procedure

Novel calcium-sensing receptor antagonist promotes PTH release in vivo

Affibody molecules -- a tool for preclinical drug profiling

Inhibitors of 11beta-HSD1: candidates for the treatment of obesity, diabetes and metabolic syndrome

Lyrica receives European approval for GAD

Aranesp approved for every-three-week dosing

New treatment options for cancer covered in recent patents

Cubist responds to approvable letter for Cubicin

Data on new chemokine CXC receptor antagonists reported at ACS meeting

Preclinical data on the antidiabetic compound SYR-322 presented

A novel target to improve memory: ghrelin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...